Hyperlipidemia Hypertriglyceridemia

Featured Products

Customer reviews
Product Description
Chapter 1: An Introduction to Cholesterol
Introduction
Cholesterol is a major structural component of all animal cells and is essential to mammalian cell function. In humans, cholesterol is an important molecular building block for steroid hormones, bile salts, and vitamin D. It is produced by the human body or digested and absorbed through the small intestine when animal products such as eggs, meat, fish, and dairy products are ingested. Healthy individuals produce approximately 1000 mg of cholesterol daily, representing approximately 75 % of the cholesterol metabolized in the human body. Intestinal daily uptake is approximately 300-500 g, representing the remaining 25 %. Cholesterol and its roles in the body are intensely studied as abnormal cholesterol metabolism can cause disease.

Table of Contents
Abbreviations and Acronyms
Introduction
Chapter 1: An Introduction to Cholesterol
Introduction
Lipid overview
Cholesterol
Carotenoids
Phospholipids
Triglycerides
Cholesterol and lipoproteins
Chylomicrons
HDL
IDL
LDL
VLDL
Apolipoproteins and lipoproteins
Cholesterol and disease
Conclusion
Chapter 2: Cholesterol Physiology
Cholesterol functions
Cholesterol catabolism
Cholesterol and bile salt synthesis
Cholesterol and steroid hormones
Cholesterol and oxysterols
Cholesterol and vitamin D
Cholesterol and lipoproteins
Chylomicrons and cholesterol metabolism
LDL and cholesterol metabolism
VLDL and cholesterol metabolism
HDL and cholesterol metabolism
Cholesterol and the plasma membrane
Cholesterol and the brain
Conclusion
Chapter 3: Cholesterol Homeostasis and Phatophysiology
Cholesterol homeostasis
De novo cholesterol biosynthesis
De novo cholesterol biosynthesis regulation
Cholesterol absorption
Dyslipidemias
Hyperlipoproteinemias
Hypercholesterolemia, atherosclerosis, and CVD
Hypocholesterolemia
Hypertriglyceridemia
Hyperalphalipoproteinemia
Hypoalphalipoproteinemia
Hepatobiliary cholesterol homeostasis
Cholesterol cholelithiasis
Cholestasis
Familial cholestasis
ICP
Cholesterol transport diseases
TD
CESD
Brain cholesterol disorders
Cholesterol and AD
Cholesterol and HD
Cholesterol and NP disease
Cholesterol and PD
Cholesterol and SLOS
Conclusion
Chapter 4: Genetics and Epigenetics of Cholesterol Homeostasis
Cholesterol and genetic, epigenetic, and environmental factors
Genetics of lipid metabolism and cholesterol homeostasis
Genetics of familial hyperlipoproteinemia
Genetics of familial hypercholesterolemia
Genetics of familial hypertriglyceridemia
Genetics of familial hyperalphalipoproteinemia
Genetics of familial hypoalphalipoproteinemia
Genetics of familial hypocholesterolemia
Abetalipoproteinemia
Hypobetalipoproteinemia
Chylomicron retention disease
Genetics of reverse cholesterol transport
Genetics of Tangier Disease
Genetics of CESD
Genetics of hepatobiliary cholesterol homeostasis
Genetics of cholesterol cholelithiasis
Genetics of cholestasis
Genetics of cholesterol brain disorders
Epigenetics of lipid metabolism and cholesterol homeostasis
DNA methylation and cholesterol
Histone modifications and cholesterol
MiRs and cholesterol
Epigenetics and dyslipidemia
Epigenetics of familial hypercholesterolemia
Conclusion
Chapter 5: Diagnosis and Management of Dyslipidemias
Hyperlipidemias
Hypercholesterolemia
Epidemiology
Symptoms
Diagnosis
Management
Diet and lifestyle modifications
Pharmacotherapy
Statins
LDL apheresis
Prognosis
Special concerns
Hypocholesterolemia
Epidemiology
Symptoms
Diagnosis
Management
Prognosis
Special concerns
Hypertriglyceridemia
Epidemiology
Symptoms
Diagnosis
Management
Prognosis
Special concerns
Cholesterol transport disorders
Tangier disease
Epidemiology
Symptoms
Diagnosis
Management
Special concerns
Cholesteryl ester storage disease
Epidemiology
Symptoms
Diagnosis
Management
Prognosis
Special concerns
Hyperalphalipoproteinemia
Epidemiology
Symptoms
Diagnosis
Manageme

Questions & answers

  1. Ray Ray says:
    How do you make noticeable down very high levels of blood serum triglyceride, without medication?
    The difficult referred to is familial hypertriglyceridemia and mixed hyperlipidemia.
    jen says:
    IF THIS DOESN'T Vocation THEN MEDICATION WILL BE NECESSARY EXERCISE AND WEIGHT LOSS ALONG WITH A LOW CHOLESTEROL Nourishment.
  1. Inveterate diseases
    Hyperlipidemia is an advance of lipids (fats ... Excess triglycerides in plasma is called hypertriglyceridemia. It's linked to the happening of coronary artery disease in some people. Notable triglycerides may be a consequence of other disease ...
  2. NHANES Analyses Support the Need for Education to Help Increased Danger Dyslipidemic Patients Aggressively Treat Their Cholesterol
    Specifically, the following three abstracts sponsored by AstraZeneca were presented: Breakdown of Moderately High-Risk Patients to About Recommended Low-Density Lipoprotein ... we do to direct the world’s most critical unmet medical needs—and ...
  3. Mochida's Epadel Inhibits Coronary Affection Disease and Reduces Recurrence - New Findings from the JELIS Goodly Scale Clinical Study
    Epadel demonstrated a statistically significant 53% peril reduction in coronary events in the patient sub-grouping with both hypertriglyceridemia ... Patients with hyperlipidemia with total cholesterol rank of 250 mg/dL and above (age range: 40 to 75 ...

New Pre-Clinical Facts on ALN-PCSsc and ALN-ANG ... - Alnylam

Send us your feedback. Capella is the brightest prominent in the constellation Auriga. For Alnylam, Capella is our online say for communicating the scientific progress we are making as we convey the science of RNAi into human clinical participation and ultimately towards the development of innovative medicines for patients.
Source: http://www.alnylam.com/capella/presentations/pre-clinical-data-aln-pcssc-aln-ang-aha2013/

Google news feed

  1. Alnylam Pharmaceuticals Inc.: Alnylam to Webcast Spectacle at Upcoming ...
    RNAi corrective targeting alpha-1-antitrypsin (AAT) for the treatment of AAT deficiency liver sickness; and ALN-ANG, an RNAi therapeutic for the treatment of genetic forms of tainted hyperlipidemia and severe hypertriglyceridemia, amongst other programs.
  2. Alnylam Earns $7 Million Milestone Payment from Genzyme for Taper off II Success ...
    RNAi medicinal targeting alpha-1-antitrypsin (AAT) for the treatment of AAT deficiency liver affliction; and ALN-ANG, an RNAi therapeutic for the treatment of genetic forms of tainted hyperlipidemia and severe hypertriglyceridemia, amongst other programs.
  3. Upcoming Webinars, FDA Clearances, Preclinical Figures Presentations ...
    pre-clinical figures from two RNAi therapeutic programs for cardiovascular affliction, including: ALN-PCSsc, for the treatment of hypercholesterolemia; and ALN-ANG, for the treatment of genetic forms of diverse hyperlipidemia and severe hypertriglyceridemia.
  4. Alnylam Presents New Pre-clinical Facts on RNAi Therapeutics for ...
    These new matter with ALN-ANG support further advancement of this program for the treatment of genetic forms of tainted hyperlipidemia and severe hypertriglyceridemia, which are associated with increased risk of coronary artery blight and/or recurrent 
  5. NHANES Analyses Fortify the Need for Education to Help Increased Jeopardize ...
    Universality of Suboptimal Non-High-Density Lipoprotein Cholesterol in U.S. Adults with Hypertriglyceridemia: the National Vigour and Nutrition Examination Survey 2003-2010(bill #15921; presented November 18) -- The authors of this interpretation found that
Letters to the Editor: Milk-Like Serum Suggests Markedly Elevated ...
Letters to the Editor: Milk-Like Serum Suggests Markedly Elevated ...
Photo Quiz: White, Opaque Fluid in a Blood Draw - American Family ...
Photo Quiz: White, Opaque Fluid in a Blood Draw - American Family ...
4mL sample of hyperlipidemic blood with lipids separated into the ...
4mL sample of hyperlipidemic blood with lipids separated into the ...